Johnson & Johnson (JNJ) 101.36 $JNJ
Better Dividend Stock: Johnson & Johnson vs. Eli Lilly and Company
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:39AM CST
Image by Geralt via Pixabay. Every investor should consider dedicating a portion of his or her portfolio to dividend-paying stocks, as companies that consistently put cash back into shareholders' pockets tend to be great performers over long...
JNJ: 101.36 (+0.14), LLY: 81.22 (-0.01)
Johnson & Johnson multiple myeloma drug wins accelerated OK
By LINDA A. JOHNSON - AP - Mon Nov 16, 4:52PM CST
TRENTON, N.J. (AP) — A Johnson & Johnson drug won Food and Drug Administration approval Monday for treating the incurable blood cancer multiple myeloma in patients who've failed prior therapies and have few options left.
JNJ: 101.36 (+0.14)
AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:27PM CST
AbbVie Inc. (ABBV) announced encouraging new data from its ongoing phase IIIb TOPAZ-II study evaluating hepatitis C virus infection drug, Viekira Pak.
JNJ: 101.36 (+0.14), GILD: 104.35 (+0.54), MRK: 53.73 (+0.03), ABBV: 60.27 (+0.26)
DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
PR Newswire - Mon Nov 16, 3:58PM CST
Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Multiple myeloma is an incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in the bone marrow.2,3 Refractory cancer occurs when a patient's disease is resistant to treatment or in the case of multiple myeloma, the disease progresses within 60 days of their last therapy.4,5 Relapsed cancer means the disease has returned after a period of initial, partial or complete remission.6
JNJ: 101.36 (+0.14)
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $101.39
Comtex SmarTrend(R) - Mon Nov 16, 1:08PM CST
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $100.19 today and have reached the first resistance level of $100.63. Investors may be interested in a cross of the next upside pivot targets of $101.39 and $102.59.
JNJ: 101.36 (+0.14)
Best Dividend Stocks for 2016
Kristine Harjes, Sean O'Reilly, Dylan Lewis, Vincent Shen, and Gaby Lapera, The Motley Fool - Motley Fool - Mon Nov 16, 7:42AM CST
Every day Foolish analysts do a deep dive on an industry in the popular podcast Industry Focus. This week we're focusing on income-generating dividend stocks -- a must-have in any retirement portfolio. See what each of our industry experts pick as...
PM: 83.82 (-0.53), JNJ: 101.36 (+0.14), SE: 27.22 (-0.19), DLR: 71.66 (+0.11), VZ: 45.04 (unch)
Global Anti-Inflammatory Therapeutics Market 2014-2020 by Indication, Drug Class & Geography
PR Newswire Europe - Mon Nov 16, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/8rkdpz/world [http://www.researchandmarkets.com/research/8rkdpz/world]) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" [http://www.researchandmarkets.com/research/8rkdpz/world] report to their offering.
JNJ: 101.36 (+0.14), PFE: 33.05 (-0.11), MRK: 53.73 (+0.03), AZN: 33.36 (+0.58), AMGN: 157.92 (+3.42), ABBV: 60.27 (+0.26), GSK: 40.58 (+0.35), NVS: 87.51 (+0.46)
Global Extremities Market Report: 2015 Edition - Major Players are Johnson & Johnson, Stryker, Zimmer and Wright Medical
M2 - Mon Nov 16, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jhjj3/global) has announced the addition of the "Global Extremities Market Report: 2015 Edition" report to their offering. This report analyzes the development of the global extremities market, with a focus on its segments including: upper extremity and lower extremity. The global market as well as the US market is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The four major players in the industry, Johnson & Johnson, Stryker, Zimmer and Wright Medical are being profiled, along with their key financials and strategies for growth. The human skeleton is typically comprised of 206 bones joined and upheld by ligaments, tendons and muscles. Because of the diversity and the specific nature of each bone or joint, the orthopedic industry has had to develop dedicated implants and related ancillaries. Prior center of the orthopedic business was focused on expansive joints, hip, knee and spine and it is just in the late times that the extremities market has earned some acknowledgment primarily on the grounds that it offers better treatment and in addition solid development opportunities. Extremity market forms a subset of joint reconstruction, which is again a subset of orthopedic industry. It can be sub-divided into two categories: lower and upper extremities, where lower extremities mainly involve ankle, foot and upper extremities involve shoulder, hand, elbow, and wrist. Shoulder replacement is the largest segment among all in the extremities market, followed by foot and ankle segment. The extremity segment holds a minimal share in the global orthopedic market as of now, mainly because the focus has been on large joints like spine, knee and hip. The extremities market is developing at the quickest rate among all sections of the orthopedics business. The market is projected to grow further in the years ahead and become specialized due to economic, social and demographic trends. Development of the industry will be driven by expanding frequency of joint pain, rising maturing populace, diabetic patients, combined with mechanical headways and thorough endeavors of makers to instruct specialists and making tolerant mindful of these items and their advantages. The progressing mergers and acquisitions and advancement of inventive extremity gadgets, emergence of startups and inserts are the key patterns seen in this industry. Key Topics Covered: 1. Market Overview 2. Market Value 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Johnson & Johnson - Smith & Nephew - Stryker - Zimmer Biomet Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/3jhjj3/global
SNN: 33.44 (+0.38), JNJ: 101.36 (+0.14), ZBH: 104.95 (-0.64)
Legal-Bay Lawsuit Settlement Funding Reports Xarelto News: Bellwether Trial Dates Announced
PR Newswire - Mon Nov 16, 4:00AM CST
Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the first bellwether trial dates in the Xarelto multidistrict litigation have been announced. U.S. District Judge Eldon Fallon will be overseeing the cases, and an order states that cases will be selected in January of 2016 from 40 lawsuits. Cases will be selected according to readiness for trial. According to an article on Reuters, the first two trials will take place in the U.S. District Court in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third trial will be heard in Mississippi on April 24th, 2017 and the fourth will take place in Texas on May 30th, 2017.
JNJ: 101.36 (+0.14)
World Anti-Inflammatory Therapeutics Market Opportunities and Forecasts, 2020 - Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion
M2 - Mon Nov 16, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/qwnb7n/world) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth. The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period. Key Topics Covered: Chapter: 1 Introduction Chapter: 2 Executive Summary Chapter: 3 Market Overview Chapter: 4 Global Anti-Inflammatory Therapeutics Market By Indication Chapter: 5 Global Anti-Inflammatory Therapeutics Market By Drug Class Chapter: 6 Global Anti-Inflammatory Therapeutics Market By Geography Chapter: 7 Company Profiles - AbbVie Inc - Amgen Inc. - AstraZeneca PLC. - Eli Lily and Company - GlaxoSmithKline plc - Hoffmann-La Roche AG - Johnson & Johnson - Merck & Co. - Novartis AG - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/qwnb7n/world
JNJ: 101.36 (+0.14), PFE: 33.05 (-0.11), MRK: 53.73 (+0.03), AZN: 33.36 (+0.58), AMGN: 157.92 (+3.42), ABBV: 60.27 (+0.26), GSK: 40.58 (+0.35), NVS: 87.51 (+0.46)
Talcum Powder Lawsuit News: Allegations Against Defendant Remain
PRWeb - Mon Nov 16, 2:03AM CST
In a national talcum powder lawsuit currently underway in St. Louis and represented by the Onder Law Firm, a chief defendant has been retained, according to the most recent court documents.* Imerys Talc America is a talc mining company that supplies raw material to the manufacturer, Johnson & Johnson, according to court documents.
JNJ: 101.36 (+0.14)
Millennials Are Investing More in Stocks Than You May Think
Matthew Frankel, The Motley Fool - Motley Fool - Sun Nov 15, 2:18PM CST
Photo: Flickr user ITU Pictures. There have been several media reports about younger investors who are scared to put their money in stocks, but there's some evidence to suggest otherwise. Here's what millennials are doing in their portfolios, and...
NFLX: 115.44 (+4.09), TSLA: 213.49 (-0.82), JNJ: 101.36 (+0.14), AMZN: 642.16 (-5.65), FB: 104.85 (+0.81), PG: 75.00 (-0.30), O: 48.44 (+0.25), AMTD: 36.19 (+0.17)
The Best Stocks in Conglomerates
Reuben Gregg Brewer, The Motley Fool - Motley Fool - Sun Nov 15, 9:15AM CST
Conglomerates go in and out of favor, with periods of mergers juxtaposed against periods of divestitures. However, there are a few names in the space that seem to make the idea of putting often disparate businesses under one roof work. The biggest...
JNJ: 101.36 (+0.14), GE: 30.05 (-0.31)
5 Things Johnson & Johnson Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 2:38PM CST
CEO Alex Gorsky. Image source: Johnson & Johnson. It's been a few weeks since healthcare conglomerate Johnson & Johnson reported its third-quarter earnings results, handily surpassing Wall Street's profit estimates once again, and...
JNJ: 101.36 (+0.14)
Johnson & Johnson Consumer Inc.'s Care to Recycle Program and Scholastic Announce Winners of National Recycling Contest: PETE's Bathroom Bin Challenge
PR Newswire - Fri Nov 13, 8:00AM CST
In celebration of America Recycles Dayi on November 15, 2015, Johnson & Johnson Consumer Inc.'s Care to Recycle® program and Scholastic today announced the winners of PETE's Bathroom Bin Challenge, a nationwide contest conducted to teach kids the importance of recycling throughout the house, including the bathroom.
JNJ: 101.36 (+0.14)
6 'Defensive-Growth' Blue-Chip Stocks for the New Year
at The Street - Thu Nov 12, 11:46AM CST
If you're concerned about market volatility but refuse to sit on the sidelines, these six growth stock stalwarts should provide both safety and capital appreciation for 2016.
JNJ: 101.36 (+0.14), WHR: 158.07 (+3.37), UTX: 97.72 (-0.11), FLT: 148.91 (+0.39), BA: 145.90 (+1.48)
Johnson & Johnson Becomes #10 Most Shorted Dow Stock, Replacing American Express
MarketNewsVideo.com - Thu Nov 12, 8:44AM CST
The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by...
JNJ: 101.36 (+0.14)
Covered Call Alerts For Apple, SPDR Gold Trust, Chevron, Johnson & Johnson and SanDisk Released By InvestorsObserver
PR Newswire - Thu Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, GLD, CVX, JNJ and SNDK.
JNJ: 101.36 (+0.14), GLD: 102.73 (-0.98), CVX: 91.09 (-0.36), AAPL: 113.75 (-0.43), SNDK: 74.66 (+0.10)
Boston Scientific Slides On Proposed Device Coverage
at Investor's Business Daily - Wed Nov 11, 4:25PM CST
Medical-device giant Boston Scientific (BSX) fell 4.2% Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Centers for Medicare and Medicaid Services (CMS) issued the proposed guidelines covering...
BSX: 17.58 (-0.16), JNJ: 101.36 (+0.14), PFE: 33.05 (-0.11)
Next Resistance Level for Johnson & Johnson (JNJ) is $102.38
Comtex SmarTrend(R) - Wed Nov 11, 9:03AM CST
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.30 today and have reached the first resistance level of $101.91. Investors may be interested in a cross of the next upside pivot targets of $102.38 and $103.46.
JNJ: 101.36 (+0.14)
Better Dividend Stock: Johnson & Johnson vs. Eli Lilly and Company
Brian Feroldi, The Motley Fool - Motley Fool - Tue Nov 17, 6:39AM CST
Image by Geralt via Pixabay. Every investor should consider dedicating a portion of his or her portfolio to dividend-paying stocks, as companies that consistently put cash back into shareholders' pockets tend to be great performers over long...
JNJ: 101.36 (+0.14), LLY: 81.22 (-0.01)
Johnson & Johnson multiple myeloma drug wins accelerated OK
By LINDA A. JOHNSON - AP - Mon Nov 16, 4:52PM CST
TRENTON, N.J. (AP) — A Johnson & Johnson drug won Food and Drug Administration approval Monday for treating the incurable blood cancer multiple myeloma in patients who've failed prior therapies and have few options left.
JNJ: 101.36 (+0.14)
AbbVie Reports Encouraging Data on HCV Drug Viekira Pak
Zacks Equity Research - Zacks Investment Research - Mon Nov 16, 4:27PM CST
AbbVie Inc. (ABBV) announced encouraging new data from its ongoing phase IIIb TOPAZ-II study evaluating hepatitis C virus infection drug, Viekira Pak.
JNJ: 101.36 (+0.14), GILD: 104.35 (+0.54), MRK: 53.73 (+0.03), ABBV: 60.27 (+0.26)
DARZALEX® (daratumumab) Approved by U.S. FDA: First Human Anti-CD38 Monoclonal Antibody Available for the Treatment of Multiple Myeloma
PR Newswire - Mon Nov 16, 3:58PM CST
Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson, announced today the U.S. Food and Drug Administration (FDA) has approved DARZALEX® (daratumumab) injection for intravenous infusion for the treatment of patients with multiple myeloma who have received at least three prior lines of therapy, including a proteasome inhibitor (PI) and an immunomodulatory agent, or who are double-refractory to a PI and an immunomodulatory agent.1 This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be contingent upon verification and description of clinical benefit in confirmatory trials. Multiple myeloma is an incurable blood cancer that occurs when malignant plasma cells grow uncontrollably in the bone marrow.2,3 Refractory cancer occurs when a patient's disease is resistant to treatment or in the case of multiple myeloma, the disease progresses within 60 days of their last therapy.4,5 Relapsed cancer means the disease has returned after a period of initial, partial or complete remission.6
JNJ: 101.36 (+0.14)
Watch for Shares of Johnson & Johnson (JNJ) to Approach Resistance at $101.39
Comtex SmarTrend(R) - Mon Nov 16, 1:08PM CST
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $100.19 today and have reached the first resistance level of $100.63. Investors may be interested in a cross of the next upside pivot targets of $101.39 and $102.59.
JNJ: 101.36 (+0.14)
Best Dividend Stocks for 2016
Kristine Harjes, Sean O'Reilly, Dylan Lewis, Vincent Shen, and Gaby Lapera, The Motley Fool - Motley Fool - Mon Nov 16, 7:42AM CST
Every day Foolish analysts do a deep dive on an industry in the popular podcast Industry Focus. This week we're focusing on income-generating dividend stocks -- a must-have in any retirement portfolio. See what each of our industry experts pick as...
PM: 83.82 (-0.53), JNJ: 101.36 (+0.14), SE: 27.22 (-0.19), DLR: 71.66 (+0.11), VZ: 45.04 (unch)
Global Anti-Inflammatory Therapeutics Market 2014-2020 by Indication, Drug Class & Geography
PR Newswire Europe - Mon Nov 16, 6:11AM CST
Research and Markets (http://www.researchandmarkets.com/research/8rkdpz/world [http://www.researchandmarkets.com/research/8rkdpz/world]) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" [http://www.researchandmarkets.com/research/8rkdpz/world] report to their offering.
JNJ: 101.36 (+0.14), PFE: 33.05 (-0.11), MRK: 53.73 (+0.03), AZN: 33.36 (+0.58), AMGN: 157.92 (+3.42), ABBV: 60.27 (+0.26), GSK: 40.58 (+0.35), NVS: 87.51 (+0.46)
Global Extremities Market Report: 2015 Edition - Major Players are Johnson & Johnson, Stryker, Zimmer and Wright Medical
M2 - Mon Nov 16, 5:01AM CST
Research and Markets (http://www.researchandmarkets.com/research/3jhjj3/global) has announced the addition of the "Global Extremities Market Report: 2015 Edition" report to their offering. This report analyzes the development of the global extremities market, with a focus on its segments including: upper extremity and lower extremity. The global market as well as the US market is being discussed in the report. The major trends, growth drivers as well as issues being faced by the industry are being presented in this report. The four major players in the industry, Johnson & Johnson, Stryker, Zimmer and Wright Medical are being profiled, along with their key financials and strategies for growth. The human skeleton is typically comprised of 206 bones joined and upheld by ligaments, tendons and muscles. Because of the diversity and the specific nature of each bone or joint, the orthopedic industry has had to develop dedicated implants and related ancillaries. Prior center of the orthopedic business was focused on expansive joints, hip, knee and spine and it is just in the late times that the extremities market has earned some acknowledgment primarily on the grounds that it offers better treatment and in addition solid development opportunities. Extremity market forms a subset of joint reconstruction, which is again a subset of orthopedic industry. It can be sub-divided into two categories: lower and upper extremities, where lower extremities mainly involve ankle, foot and upper extremities involve shoulder, hand, elbow, and wrist. Shoulder replacement is the largest segment among all in the extremities market, followed by foot and ankle segment. The extremity segment holds a minimal share in the global orthopedic market as of now, mainly because the focus has been on large joints like spine, knee and hip. The extremities market is developing at the quickest rate among all sections of the orthopedics business. The market is projected to grow further in the years ahead and become specialized due to economic, social and demographic trends. Development of the industry will be driven by expanding frequency of joint pain, rising maturing populace, diabetic patients, combined with mechanical headways and thorough endeavors of makers to instruct specialists and making tolerant mindful of these items and their advantages. The progressing mergers and acquisitions and advancement of inventive extremity gadgets, emergence of startups and inserts are the key patterns seen in this industry. Key Topics Covered: 1. Market Overview 2. Market Value 3. Market Dynamics 4. Competitive Landscape 5. Company Profiles 6. Market Outlook Companies Mentioned - Johnson & Johnson - Smith & Nephew - Stryker - Zimmer Biomet Holdings, Inc. For more information visit http://www.researchandmarkets.com/research/3jhjj3/global
SNN: 33.44 (+0.38), JNJ: 101.36 (+0.14), ZBH: 104.95 (-0.64)
Legal-Bay Lawsuit Settlement Funding Reports Xarelto News: Bellwether Trial Dates Announced
PR Newswire - Mon Nov 16, 4:00AM CST
Legal-Bay LLC, The Lawsuit Settlement Funding Company, reports today that the first bellwether trial dates in the Xarelto multidistrict litigation have been announced. U.S. District Judge Eldon Fallon will be overseeing the cases, and an order states that cases will be selected in January of 2016 from 40 lawsuits. Cases will be selected according to readiness for trial. According to an article on Reuters, the first two trials will take place in the U.S. District Court in the Eastern District of Louisiana on February 6th and March 13th of 2017. The third trial will be heard in Mississippi on April 24th, 2017 and the fourth will take place in Texas on May 30th, 2017.
JNJ: 101.36 (+0.14)
World Anti-Inflammatory Therapeutics Market Opportunities and Forecasts, 2020 - Anti-inflammatory Therapeutics Market is Expected to Reach $106.1 Billion
M2 - Mon Nov 16, 2:47AM CST
Research and Markets (http://www.researchandmarkets.com/research/qwnb7n/world) has announced the addition of the "World Anti-Inflammatory Therapeutics Market - Opportunities and Forecasts, 2014 - 2020" report to their offering. The global anti-inflammatory therapeutics market is expected to grow at a CAGR of 5.9% over the forecast period, owing to the emergence of anti-inflammatory biologics that are more targeted, effective and with lesser side effects as compared to conventional drugs. In addition, they are also difficult to imitate due to their complex molecular structure and origin. The global anti-inflammatory market has been driven by factors such as increasing autoimmune and respiratory conditions, new drugs in pipeline and increasing adoption of anti-inflammatory drugs. Moreover, increasing awareness of anti-inflammatory therapeutics and attractive government initiatives in the Asia-Pacific and LAMEA region are expected to drive the market during the analysis period. Factors, such as side effects of anti-inflammatory drugs and patent expiry issues of blockbuster drugs (such as Remicade), are known to impede the market growth. The global anti-inflammatory therapeutics market is segmented on the basis of indication, drug class and geography. The indications considered in this report include arthritis, respiratory diseases, multiple sclerosis, psoriasis, inflammatory bowel disease and other inflammatory diseases. Among indications, arthritis holds tremendous potential for growth accounting for 38.2% of the global anti-inflammatory therapeutics market. Anti-inflammatory biologics are the most preferred drugs for treatment of arthritis. On the basis of drug class, the market is segmented into anti-inflammatory biologics, non-steroidal anti-inflammatory drugs (NSAIDs) and corticosteroids. Anti-inflammatory biologics holds the largest share among drug classes accounting for 54.8% share of the global anti-inflammatory therapeutics market, and is expected grow rapidly during the forecast period. Key Topics Covered: Chapter: 1 Introduction Chapter: 2 Executive Summary Chapter: 3 Market Overview Chapter: 4 Global Anti-Inflammatory Therapeutics Market By Indication Chapter: 5 Global Anti-Inflammatory Therapeutics Market By Drug Class Chapter: 6 Global Anti-Inflammatory Therapeutics Market By Geography Chapter: 7 Company Profiles - AbbVie Inc - Amgen Inc. - AstraZeneca PLC. - Eli Lily and Company - GlaxoSmithKline plc - Hoffmann-La Roche AG - Johnson & Johnson - Merck & Co. - Novartis AG - Pfizer Inc For more information visit http://www.researchandmarkets.com/research/qwnb7n/world
JNJ: 101.36 (+0.14), PFE: 33.05 (-0.11), MRK: 53.73 (+0.03), AZN: 33.36 (+0.58), AMGN: 157.92 (+3.42), ABBV: 60.27 (+0.26), GSK: 40.58 (+0.35), NVS: 87.51 (+0.46)
Talcum Powder Lawsuit News: Allegations Against Defendant Remain
PRWeb - Mon Nov 16, 2:03AM CST
In a national talcum powder lawsuit currently underway in St. Louis and represented by the Onder Law Firm, a chief defendant has been retained, according to the most recent court documents.* Imerys Talc America is a talc mining company that supplies raw material to the manufacturer, Johnson & Johnson, according to court documents.
JNJ: 101.36 (+0.14)
Millennials Are Investing More in Stocks Than You May Think
Matthew Frankel, The Motley Fool - Motley Fool - Sun Nov 15, 2:18PM CST
Photo: Flickr user ITU Pictures. There have been several media reports about younger investors who are scared to put their money in stocks, but there's some evidence to suggest otherwise. Here's what millennials are doing in their portfolios, and...
NFLX: 115.44 (+4.09), TSLA: 213.49 (-0.82), JNJ: 101.36 (+0.14), AMZN: 642.16 (-5.65), FB: 104.85 (+0.81), PG: 75.00 (-0.30), O: 48.44 (+0.25), AMTD: 36.19 (+0.17)
The Best Stocks in Conglomerates
Reuben Gregg Brewer, The Motley Fool - Motley Fool - Sun Nov 15, 9:15AM CST
Conglomerates go in and out of favor, with periods of mergers juxtaposed against periods of divestitures. However, there are a few names in the space that seem to make the idea of putting often disparate businesses under one roof work. The biggest...
JNJ: 101.36 (+0.14), GE: 30.05 (-0.31)
5 Things Johnson & Johnson Wants You to Know
Sean Williams, The Motley Fool - Motley Fool - Fri Nov 13, 2:38PM CST
CEO Alex Gorsky. Image source: Johnson & Johnson. It's been a few weeks since healthcare conglomerate Johnson & Johnson reported its third-quarter earnings results, handily surpassing Wall Street's profit estimates once again, and...
JNJ: 101.36 (+0.14)
Johnson & Johnson Consumer Inc.'s Care to Recycle Program and Scholastic Announce Winners of National Recycling Contest: PETE's Bathroom Bin Challenge
PR Newswire - Fri Nov 13, 8:00AM CST
In celebration of America Recycles Dayi on November 15, 2015, Johnson & Johnson Consumer Inc.'s Care to Recycle® program and Scholastic today announced the winners of PETE's Bathroom Bin Challenge, a nationwide contest conducted to teach kids the importance of recycling throughout the house, including the bathroom.
JNJ: 101.36 (+0.14)
6 'Defensive-Growth' Blue-Chip Stocks for the New Year
at The Street - Thu Nov 12, 11:46AM CST
If you're concerned about market volatility but refuse to sit on the sidelines, these six growth stock stalwarts should provide both safety and capital appreciation for 2016.
JNJ: 101.36 (+0.14), WHR: 158.07 (+3.37), UTX: 97.72 (-0.11), FLT: 148.91 (+0.39), BA: 145.90 (+1.48)
Johnson & Johnson Becomes #10 Most Shorted Dow Stock, Replacing American Express
MarketNewsVideo.com - Thu Nov 12, 8:44AM CST
The most recent short interest data has been released by the NASDAQ for the 10/30/2015 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by...
JNJ: 101.36 (+0.14)
Covered Call Alerts For Apple, SPDR Gold Trust, Chevron, Johnson & Johnson and SanDisk Released By InvestorsObserver
PR Newswire - Thu Nov 12, 8:31AM CST
InvestorsObserver issues critical PriceWatch Alerts for AAPL, GLD, CVX, JNJ and SNDK.
JNJ: 101.36 (+0.14), GLD: 102.73 (-0.98), CVX: 91.09 (-0.36), AAPL: 113.75 (-0.43), SNDK: 74.66 (+0.10)
Boston Scientific Slides On Proposed Device Coverage
at Investor's Business Daily - Wed Nov 11, 4:25PM CST
Medical-device giant Boston Scientific (BSX) fell 4.2% Wednesday after the U.S. government proposed limiting coverage of its new heart implant. Late Tuesday, the Centers for Medicare and Medicaid Services (CMS) issued the proposed guidelines covering...
BSX: 17.58 (-0.16), JNJ: 101.36 (+0.14), PFE: 33.05 (-0.11)
Next Resistance Level for Johnson & Johnson (JNJ) is $102.38
Comtex SmarTrend(R) - Wed Nov 11, 9:03AM CST
Shares of Johnson & Johnson (NYSE:JNJ) have bullishly opened above the pivot of $101.30 today and have reached the first resistance level of $101.91. Investors may be interested in a cross of the next upside pivot targets of $102.38 and $103.46.
JNJ: 101.36 (+0.14)
